270 related articles for article (PubMed ID: 21308371)
1. 18F-FDG PET independently predicts survival in patients with cholangiocellular carcinoma treated with 90Y microspheres.
Haug AR; Heinemann V; Bruns CJ; Hoffmann R; Jakobs T; Bartenstein P; Hacker M
Eur J Nucl Med Mol Imaging; 2011 Jun; 38(6):1037-45. PubMed ID: 21308371
[TBL] [Abstract][Full Text] [Related]
2. 18F-FDG PET/CT predicts survival after radioembolization of hepatic metastases from breast cancer.
Haug AR; Tiega Donfack BP; Trumm C; Zech CJ; Michl M; Laubender RP; Uebleis C; Bartenstein P; Heinemann V; Hacker M
J Nucl Med; 2012 Mar; 53(3):371-7. PubMed ID: 22331219
[TBL] [Abstract][Full Text] [Related]
3. Radioembolization with (90)Y resin microspheres for intrahepatic cholangiocellular carcinoma: prognostic factors.
Soydal C; Kucuk ON; Bilgic S; Ibis E
Ann Nucl Med; 2016 Jan; 30(1):29-34. PubMed ID: 26370716
[TBL] [Abstract][Full Text] [Related]
4. Predictive value of intratumoral 99mTc-macroaggregated albumin uptake in patients with colorectal liver metastases scheduled for radioembolization with 90Y-microspheres.
Ulrich G; Dudeck O; Furth C; Ruf J; Grosser OS; Adolf D; Stiebler M; Ricke J; Amthauer H
J Nucl Med; 2013 Apr; 54(4):516-22. PubMed ID: 23447653
[TBL] [Abstract][Full Text] [Related]
5.
Nezami N; Kokabi N; Camacho JC; Schuster DM; Xing M; Kim HS
Nucl Med Biol; 2018 Apr; 59():22-28. PubMed ID: 29448165
[TBL] [Abstract][Full Text] [Related]
6. Dosimetry based on 99mTc-macroaggregated albumin SPECT/CT accurately predicts tumor response and survival in hepatocellular carcinoma patients treated with 90Y-loaded glass microspheres: preliminary results.
Garin E; Lenoir L; Rolland Y; Edeline J; Mesbah H; Laffont S; Porée P; Clément B; Raoul JL; Boucher E
J Nucl Med; 2012 Feb; 53(2):255-63. PubMed ID: 22302962
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of neutrophil-to-lymphocyte ratio and its correlation with fluorine-18-fluorodeoxyglucose metabolic parameters in intrahepatic cholangiocarcinoma submitted to 90Y-radioembolization.
Filippi L; Di Costanzo GG; Tortora R; Pelle G; Saltarelli A; Marino Marsilia G; Cianni R; Schillaci O; Bagni O
Nucl Med Commun; 2020 Jan; 41(1):78-86. PubMed ID: 31800510
[TBL] [Abstract][Full Text] [Related]
8. PET response criteria for solid tumors predict survival at three months after intra-arterial resin-based 90Yttrium radioembolization therapy for unresectable intrahepatic cholangiocarcinoma.
Camacho JC; Kokabi N; Xing M; Schuster DM; Kim HS
Clin Nucl Med; 2014 Nov; 39(11):944-50. PubMed ID: 25140563
[TBL] [Abstract][Full Text] [Related]
9. Early post-treatment FDG PET predicts survival after 90Y microsphere radioembolization in liver-dominant metastatic colorectal cancer.
Sabet A; Meyer C; Aouf A; Sabet A; Ghamari S; Pieper CC; Mayer K; Biersack HJ; Ezziddin S
Eur J Nucl Med Mol Imaging; 2015 Mar; 42(3):370-6. PubMed ID: 25351506
[TBL] [Abstract][Full Text] [Related]
10. Change in total lesion glycolysis and clinical outcome after (90)Y radioembolization in intrahepatic cholangiocarcinoma.
Filippi L; Pelle G; Cianni R; Scopinaro F; Bagni O
Nucl Med Biol; 2015 Jan; 42(1):59-64. PubMed ID: 25213104
[TBL] [Abstract][Full Text] [Related]
11. Predictive Value of 99mTc-MAA SPECT for 90Y-Labeled Resin Microsphere Distribution in Radioembolization of Primary and Secondary Hepatic Tumors.
Ilhan H; Goritschan A; Paprottka P; Jakobs TF; Fendler WP; Todica A; Bartenstein P; Hacker M; Haug AR
J Nucl Med; 2015 Nov; 56(11):1654-60. PubMed ID: 26315830
[TBL] [Abstract][Full Text] [Related]
12. Feasibility of temporary protective embolization of normal liver tissue using degradable starch microspheres during radioembolization of liver tumours.
Meyer C; Pieper CC; Ezziddin S; Wilhelm KE; Schild HH; Ahmadzadehfar H
Eur J Nucl Med Mol Imaging; 2014 Feb; 41(2):231-7. PubMed ID: 24030669
[TBL] [Abstract][Full Text] [Related]
13. 90Y Radioembolization Lung Shunt Fraction in Primary and Metastatic Liver Cancer as a Biomarker for Survival.
Xing M; Lahti S; Kokabi N; Schuster DM; Camacho JC; Kim HS
Clin Nucl Med; 2016 Jan; 41(1):21-7. PubMed ID: 26222534
[TBL] [Abstract][Full Text] [Related]
14. SPECT/CT with 99mTc-MAA in radioembolization with 90Y microspheres in patients with hepatocellular cancer.
Hamami ME; Poeppel TD; Müller S; Heusner T; Bockisch A; Hilgard P; Antoch G
J Nucl Med; 2009 May; 50(5):688-92. PubMed ID: 19372479
[TBL] [Abstract][Full Text] [Related]
15. The role of early ¹⁸F-FDG PET/CT in prediction of progression-free survival after ⁹⁰Y radioembolization: comparison with RECIST and tumour density criteria.
Zerizer I; Al-Nahhas A; Towey D; Tait P; Ariff B; Wasan H; Hatice G; Habib N; Barwick T
Eur J Nucl Med Mol Imaging; 2012 Sep; 39(9):1391-9. PubMed ID: 22644713
[TBL] [Abstract][Full Text] [Related]
16. A simple method for estimating dose delivered to hepatocellular carcinoma after yttrium-90 glass-based radioembolization therapy: preliminary results of a proof of concept study.
Kokabi N; Galt JR; Xing M; Camacho JC; Barron BJ; Schuster DM; Kim HS
J Vasc Interv Radiol; 2014 Feb; 25(2):277-87. PubMed ID: 24461133
[TBL] [Abstract][Full Text] [Related]
17. Survival in patients with hepatocellular carcinoma treated with 90Y-microsphere radioembolization. Prediction by 18F-FDG PET.
Sabet A; Ahmadzadehfar H; Bruhman J; Sabet A; Meyer C; Wasmuth JC; Pieper CC; Biersack HJ; Ezziddin S
Nuklearmedizin; 2014; 53(2):39-45. PubMed ID: 24777354
[TBL] [Abstract][Full Text] [Related]
18. Personalised radioembolization improves outcomes in refractory intra-hepatic cholangiocarcinoma: a multicenter study.
Levillain H; Duran Derijckere I; Ameye L; Guiot T; Braat A; Meyer C; Vanderlinden B; Reynaert N; Hendlisz A; Lam M; Deroose CM; Ahmadzadehfar H; Flamen P
Eur J Nucl Med Mol Imaging; 2019 Oct; 46(11):2270-2279. PubMed ID: 31324943
[TBL] [Abstract][Full Text] [Related]
19. Radioembolization with
Ho CL; Chen S; Cheung SK; Leung YL; Cheng KC; Wong KN; Wong YH; Leung TWT
Eur J Nucl Med Mol Imaging; 2018 Nov; 45(12):2110-2121. PubMed ID: 29948107
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of factors affecting tumor response and survival in patients with primary and metastatic liver cancer treated with microspheres.
Demirelli S; Erkilic M; Oner AO; Budak ES; Gunduz S; Ozgur O; Bozcuk H; Sindel HT; Boz A
Nucl Med Commun; 2015 Apr; 36(4):340-9. PubMed ID: 25563137
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
